Formulation Strategies for Bioactive Compounds of Kyllinga Triceps in The Management of Diabetes Mellitus: A Comprehensive Review

Diabetes mellitus is a chronic metabolic disorder defined by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The increasing global burden of diabetes and the limitations of current therapies have intensified research into plant-derived bioactive compounds as alternative or complementary hypoglycemic agents. Traditional medicinal systems in India have long used Kyllinga triceps (Cyperaceae) for managing symptoms associated with diabetes, supporting ethnobotanical claims of its therapeutic potential. Phytochemical investigations reveal that K. triceps contains significant levels of flavonoids, sterols, phenolics, and other secondary metabolites, many of which are linked to antidiabetic mechanisms such as carbohydrate-digesting enzyme inhibition, antioxidant activity, and insulin sensitization. Experimental studies in diabetic animal models indicate that extracts of K. triceps and its fractions produce meaningful reductions in blood glucose levels, validating aspects of its traditional use and suggesting possible pharmacological relevance. Despite promising pharmacodynamic data, therapeutic translation requires addressing challenges related to the stability, solubility, bioavailability, and targeted delivery of its bioactive constituents. This review synthesizes current evidence on the phytochemistry, and antidiabetic pharmacology of K. triceps, and outlines formulation strategies that enhance the clinical potential of its bioactive compounds. Approaches such as extract standardization, solubility enhancement, nano- and microencapsulation, controlled release systems, and synergistic herbal combinations are evaluated for their ability to improve systemic exposure and therapeutic efficacy. Mechanistic insights are discussed in the context of known bioactive classes, including their roles in modulating key diabetes-related pathways such as carbohydrate digestion, oxidative stress, insulin signaling, and glucose uptake. Finally, gaps in current research are identified, and future directions are proposed to guide comprehensive preclinical and clinical evaluation. This evidence-based framework aims to support the development of safe, effective, and scalable antidiabetic formulations derived from Kyllinga triceps bioactives, aligning traditional knowledge with modern pharmaceutical science.